chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amnesia, Body temperature, COVID-19 immunisation, Chills, Cold sweat
Clinical narrative: Sweats; Covid 19 immnunization; Interchange of vaccine products; Dizziness; Nausea; Fatigue; Fever; Chills; This spontaneous case was reported by a patient and describes the occurrence of HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051f21a) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient was plenty healthy. Her auto immune markers have diminished.  The patient's past medical history included Walker user (had to use back in 2016 when she first came down with autoimmune issues) in 2016, Lyme disease (She was pretty healthy until she got what considered to be Lyme disease on 2015) in 2015 and Near death experience (she really was dying in 2016 and had to be hospitalized for a month) in 2016. Previously administered products included for Product used for unknown indication: J and J (Lot#1805025 and first dose) on 13-Mar-2021. Past adverse reactions to the above products included No adverse event with J and J. Concurrent medical conditions included Asthma, Pollen allergy (allergic to tree pollen), Allergy to molds and Antiphospholipid syndrome (complex of autoimmune disorders back in 2016, a serious heart autoimmune disorder or a blood autoimmune disorder called APS antiphospholipid syndrome) since 2016.    On 11-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (Sweats), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills) had resolved and COVID-19 IMMUNISATION (Covid 19 immnunization) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            No concomitant medications were reported.   It was reported that patient experienced life threatening adverse reaction to Moderna's Boosters.  Following vaccination with the 1st Moderna booster patient experienced adverse reaction of nausea, fatigue, fever, sweats, chills, dizziness and it went away by the 3rd day.  Patient did not had COVID positive test or diagnosis and never had symptoms for COVID.   No treatment medication was provided.   This case was linked to MOD-2022-674780, MOD-2022-674779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2022: Follow-up received included added.
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysstasia, Fatigue, Feeling cold, Head discomfort, Illness
Clinical narrative: Sweats; Covid 19 immnunization; Interchange of vaccine products; Dizziness; Nausea; Fatigue; Fever; Chills; This spontaneous case was reported by a patient and describes the occurrence of HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051f21a) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient was plenty healthy. Her auto immune markers have diminished.  The patient's past medical history included Walker user (had to use back in 2016 when she first came down with autoimmune issues) in 2016, Lyme disease (She was pretty healthy until she got what considered to be Lyme disease on 2015) in 2015 and Near death experience (she really was dying in 2016 and had to be hospitalized for a month) in 2016. Previously administered products included for Product used for unknown indication: J and J (Lot#1805025 and first dose) on 13-Mar-2021. Past adverse reactions to the above products included No adverse event with J and J. Concurrent medical conditions included Asthma, Pollen allergy (allergic to tree pollen), Allergy to molds and Antiphospholipid syndrome (complex of autoimmune disorders back in 2016, a serious heart autoimmune disorder or a blood autoimmune disorder called APS antiphospholipid syndrome) since 2016.    On 11-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (Sweats), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills) had resolved and COVID-19 IMMUNISATION (Covid 19 immnunization) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            No concomitant medications were reported.   It was reported that patient experienced life threatening adverse reaction to Moderna's Boosters.  Following vaccination with the 1st Moderna booster patient experienced adverse reaction of nausea, fatigue, fever, sweats, chills, dizziness and it went away by the 3rd day.  Patient did not had COVID positive test or diagnosis and never had symptoms for COVID.   No treatment medication was provided.   This case was linked to MOD-2022-674780, MOD-2022-674779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2022: Follow-up received included added.
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products, Limb discomfort, Loss of consciousness, Mobility decreased, Nausea
Clinical narrative: Sweats; Covid 19 immnunization; Interchange of vaccine products; Dizziness; Nausea; Fatigue; Fever; Chills; This spontaneous case was reported by a patient and describes the occurrence of HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051f21a) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient was plenty healthy. Her auto immune markers have diminished.  The patient's past medical history included Walker user (had to use back in 2016 when she first came down with autoimmune issues) in 2016, Lyme disease (She was pretty healthy until she got what considered to be Lyme disease on 2015) in 2015 and Near death experience (she really was dying in 2016 and had to be hospitalized for a month) in 2016. Previously administered products included for Product used for unknown indication: J and J (Lot#1805025 and first dose) on 13-Mar-2021. Past adverse reactions to the above products included No adverse event with J and J. Concurrent medical conditions included Asthma, Pollen allergy (allergic to tree pollen), Allergy to molds and Antiphospholipid syndrome (complex of autoimmune disorders back in 2016, a serious heart autoimmune disorder or a blood autoimmune disorder called APS antiphospholipid syndrome) since 2016.    On 11-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (Sweats), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills) had resolved and COVID-19 IMMUNISATION (Covid 19 immnunization) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            No concomitant medications were reported.   It was reported that patient experienced life threatening adverse reaction to Moderna's Boosters.  Following vaccination with the 1st Moderna booster patient experienced adverse reaction of nausea, fatigue, fever, sweats, chills, dizziness and it went away by the 3rd day.  Patient did not had COVID positive test or diagnosis and never had symptoms for COVID.   No treatment medication was provided.   This case was linked to MOD-2022-674780, MOD-2022-674779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2022: Follow-up received included added.
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Neck pain, Pyrexia, Retching, Syncope, Vomiting
Clinical narrative: Sweats; Covid 19 immnunization; Interchange of vaccine products; Dizziness; Nausea; Fatigue; Fever; Chills; This spontaneous case was reported by a patient and describes the occurrence of HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051f21a) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Patient was plenty healthy. Her auto immune markers have diminished.  The patient's past medical history included Walker user (had to use back in 2016 when she first came down with autoimmune issues) in 2016, Lyme disease (She was pretty healthy until she got what considered to be Lyme disease on 2015) in 2015 and Near death experience (she really was dying in 2016 and had to be hospitalized for a month) in 2016. Previously administered products included for Product used for unknown indication: J and J (Lot#1805025 and first dose) on 13-Mar-2021. Past adverse reactions to the above products included No adverse event with J and J. Concurrent medical conditions included Asthma, Pollen allergy (allergic to tree pollen), Allergy to molds and Antiphospholipid syndrome (complex of autoimmune disorders back in 2016, a serious heart autoimmune disorder or a blood autoimmune disorder called APS antiphospholipid syndrome) since 2016.    On 11-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Sweats), COVID-19 IMMUNISATION (Covid 19 immnunization), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (Sweats), DIZZINESS (Dizziness), NAUSEA (Nausea), FATIGUE (Fatigue), PYREXIA (Fever) and CHILLS (Chills) had resolved and COVID-19 IMMUNISATION (Covid 19 immnunization) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            No concomitant medications were reported.   It was reported that patient experienced life threatening adverse reaction to Moderna's Boosters.  Following vaccination with the 1st Moderna booster patient experienced adverse reaction of nausea, fatigue, fever, sweats, chills, dizziness and it went away by the 3rd day.  Patient did not had COVID positive test or diagnosis and never had symptoms for COVID.   No treatment medication was provided.   This case was linked to MOD-2022-674780, MOD-2022-674779 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2022: Follow-up received included added.
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient was given the monovalent vaccine as booster; This spontaneous case was reported by a patient and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient was given the monovalent vaccine as booster) and NO ADVERSE EVENT (No adverse event) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Sep-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient was given the monovalent vaccine as booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient was given the monovalent vaccine as booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      No concomitant information provided. Caller stated that both she and her husband got the Moderna bivalent vaccine on 07Sep2022. Her husband just got back from his doctor and was told that this was not the bivalent that they got but the old one. No treatment information provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-675039 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-675039:Husband's case
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: Given the bivlaent as 2nd dose of the primary series; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Given the bivlaent as 2nd dose of the primary series) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Given the bivlaent as 2nd dose of the primary series) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Given the bivlaent as 2nd dose of the primary series) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Given the bivlaent as 2nd dose of the primary series).    Concomitant medication was not provided.  Pharmacist reported that inadvertently administered the bivalent dose to a patient who had one dose of the primary series.  Treatment information was not provided.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain
Clinical narrative: sore injection site arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore injection site arm) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Heart disorder (Heart problems), Type 2 diabetes mellitus (Type 2 Diabetes) and Kidney disorder (Kidney problems).   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Feb-2021, the patient experienced VACCINATION SITE PAIN (sore injection site arm). At the time of the report, VACCINATION SITE PAIN (sore injection site arm) outcome was unknown.            No concomitant medications were reported.  After receiving both the first and second doses of Moderna vaccine, the patient experienced sore injection site arm.  No treatment medications were reported.   This case was linked to MOD-2022-675037 (Patient Link).
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood glucose, Vaccination site pain
Clinical narrative: sore injection site arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore injection site arm) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Heart disorder (Heart problems), Type 2 diabetes mellitus (Type 2 Diabetes) and Kidney disorder (Kidney problems).   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Feb-2021, the patient experienced VACCINATION SITE PAIN (sore injection site arm). At the time of the report, VACCINATION SITE PAIN (sore injection site arm) outcome was unknown.            No concomitant medications were reported.  After receiving both the first and second doses of Moderna vaccine, the patient experienced sore injection site arm.  No treatment medications were reported.   This case was linked to MOD-2022-675037 (Patient Link).
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vaccination site pain
Clinical narrative: sore injection site arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore injection site arm) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Heart disorder, Type 2 diabetes mellitus and Kidney disorder.   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (sore injection site arm). At the time of the report, VACCINATION SITE PAIN (sore injection site arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: The blood glucose went to 450..  The patient's height was 170.6 cm. No concomitant medication was reported.  No treatment medication was reported.   This case was linked to MOD-2022-675033 (Patient Link).
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood glucose, Vaccination site pain
Clinical narrative: sore injection site arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore injection site arm) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Heart disorder, Type 2 diabetes mellitus and Kidney disorder.   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (sore injection site arm). At the time of the report, VACCINATION SITE PAIN (sore injection site arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: The blood glucose went to 450..  The patient's height was 170.6 cm. No concomitant medication was reported.  No treatment medication was reported.   This case was linked to MOD-2022-675033 (Patient Link).
Age: 20.0
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient received bivalent booster as second dose; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received bivalent booster as second dose) and NO ADVERSE EVENT (No adverse event) in a 20-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Nov-2022, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 18-Nov-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received bivalent booster as second dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received bivalent booster as second dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received bivalent booster as second dose).    No concomitant medications were reported. On 19-Oct-2022, Patient received first dose of Moderna COVID-19 vaccine monovalent of unknown Batch number. No treatment information was provided.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient received the Moderna bivalent instead of monovalent for his 1st dose; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent instead of monovalent for his 1st dose) and NO ADVERSE EVENT (No adverse event) in a 54-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 015H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Nov-2022, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 11-Nov-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent instead of monovalent for his 1st dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent instead of monovalent for his 1st dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received the Moderna bivalent instead of monovalent for his 1st dose).    No concomitant medications were reported. HCP  already got a recommendation from the CDC to repeat the monovalent primary dose on the same day.  Therefore, since patient was still at the facility at the time, patient received a dose of the monovalent Moderna COVID-19 vaccine on 11-NOV2022  of Lot: 083B22A, Expiration date 25-NOV-2022. Patient had not reported any adverse reactions. No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Nervous system disorder
Clinical narrative: Neurological consequences; This spontaneous case was reported by a patient family member or friend and describes the occurrence of NERVOUS SYSTEM DISORDER (Neurological consequences) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NERVOUS SYSTEM DISORDER (Neurological consequences). At the time of the report, NERVOUS SYSTEM DISORDER (Neurological consequences) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication details was reported.  No treatment medication details was reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-675055, US-MODERNATX, INC.-MOD-2022-675276 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-675055:Patient  US-MODERNATX, INC.-MOD-2022-675276:Reporter's case
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, COVID-19, Feeling hot, SARS-CoV-2 test
Clinical narrative: but felt hotter; tested positive for covid (Developed a sore throat/ fever of 98.8/ cough/ thought it was a cold); This spontaneous case was reported by a patient and describes the occurrence of FEELING HOT (but felt hotter) and COVID-19 (tested positive for covid (Developed a sore throat/ fever of 98.8/ cough/ thought it was a cold)) in a 57-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 013H22A) for COVID-19 prophylaxis.     Previously administered products included for Drug use for unknown indication: JANSSEN COVID-19 VACCINE (Dose Number: 1 Lot number: 1805025) on 12-Mar-2021. Past adverse reactions to the above products included No adverse event with JANSSEN COVID-19 VACCINE.    On 10-Nov-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 15-Nov-2022, the patient experienced FEELING HOT (but felt hotter) and COVID-19 (tested positive for covid (Developed a sore throat/ fever of 98.8/ cough/ thought it was a cold)). At the time of the report, FEELING HOT (but felt hotter) and COVID-19 (tested positive for covid (Developed a sore throat/ fever of 98.8/ cough/ thought it was a cold)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Nov-2022, Body temperature: 98.8, but felt hotter than that. On 15-Nov-2022, SARS-CoV-2 test: Positive.         No concomitant medications were reported. The patient received Moderna Booster 1 with dose of 0.25 ml (Lot number: 037C21A) on an unknow date. On 23-Mar-2022, the patient received Moderna Booster 2 (Lot number: 056A22A).   Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Nov-2022: Follow-up contains no new information.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: the vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022; No adverse event; bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022), PRODUCT STORAGE ERROR (the vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 051d22a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 18-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (the vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022), PRODUCT STORAGE ERROR (the vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022) and PRODUCT STORAGE ERROR (the vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022).    No concomitant medication details was reported. It was reported that individual vails was used and vial size was reported as 2.5ml. The vial did not undergo any temperature excursions. No treatment medication details was reported.   This case contains information for the 1st of 14 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-675260, US-MODERNATX, INC.-MOD-2022-675264, US-MODERNATX, INC.-MOD-2022-675268 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-675260:Patient 1 US-MODERNATX, INC.-MOD-2022-675264:same reporter US-MODERNATX, INC.-MOD-2022-675268:Patient 1
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vial was initially stored in refrigerator on 18-Oct-2022, vaccine use by date was 17-NOV-2022,dose was administered on 18-NOV-2022.; No adverse event; bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022), PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 18-Oct-2022, vaccine use by date was 17-NOV-2022,dose was administered on 18-NOV-2022.) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 051d22a) for COVID-19 prophylaxis.     No Medical History information was reported.   On 18-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 18-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 18-Oct-2022, vaccine use by date was 17-NOV-2022,dose was administered on 18-NOV-2022.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022), PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 18-Oct-2022, vaccine use by date was 17-NOV-2022,dose was administered on 18-NOV-2022.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022) and PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 18-Oct-2022, vaccine use by date was 17-NOV-2022,dose was administered on 18-NOV-2022.).    No concomitant medications were reported. Vial size was reported as 2.5mL.Vial was initially stored in the refrigerator on 18-Oct-2022.Vaccine use by date was 17-NOV-2022. Vial did not underwent any temperature excursions. No treatment information was provided. This case was reported for adult patient 6 out of 14 patients.   This case was linked to US-MODERNATX, INC.-MOD-2022-675260, US-MODERNATX, INC.-MOD-2022-675264, US-MODERNATX, INC.-MOD-2022-675268 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-675260:Patient 6 US-MODERNATX, INC.-MOD-2022-675264:same reporter US-MODERNATX, INC.-MOD-2022-675268:Patient 6
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022.; No adverse event; bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022), PRODUCT STORAGE ERROR (vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022.) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 051d22a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 18-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 18-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022), PRODUCT STORAGE ERROR (vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17Nov2022) and PRODUCT STORAGE ERROR (vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022.).    No concomitant drug was reported. The vial size was reported as 2.5 ml. The vial was initially stored in the refrigerator on 18-Oct-2022, before use date was 17-Nov-2022,  the administration of vaccine was on 18-Nov-2022. It was reported that the vial did not undergo any temperature excursions.  No treatment drug was reported. This case contains information for the 7th of 14 adult patients described by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022; No adverse event; Bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 051d22a) for COVID-19 prophylaxis.     No Medical History information was reported.   On 18-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 18-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Bivalent Moderna COVID19 vaccine were given after the beyond use date BUD 17-Nov-2022) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 18-Oct-2022 and vaccine administered on 18-Nov-2022).    Concomitant medication was not provided.  Reporter reported that the vial was individual vial and size was 2.5 ml. The vial was initially stored in the refrigerator on 18-oct-2022. The vial did not undergo any temperature excursions.  Treatment information was not provided.  This case contains information for the 9th of 14 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2022-675260, US-MODERNATX, INC.-MOD-2022-675264, US-MODERNATX, INC.-MOD-2022-675268 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-675260: US-MODERNATX, INC.-MOD-2022-675264:same reporter US-MODERNATX, INC.-MOD-2022-675268:
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: She got Covid in January; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (She got Covid in January) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer COVID-19 (1st dose; Route of Administration: Intramuscular) in April 2021, Pfizer COVID-19 (2nd dose; Route of Administration: Intramuscular. She had the 2nd part of the 1st vaccine and the vaccine was put in her shoulder capsule and had nerve pain and couldn't move her arm.) on 15-Jul-2021. Past adverse reactions to the above products included Mobility decreased with Pfizer COVID-19; and No adverse effect with Pfizer COVID-19. Concurrent medical conditions included Hyperthyroidism. Concomitant products included METHIMAZOLE for Thyroid disorder NOS.   On 01-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2022, the patient experienced COVID-19 (She got Covid in January). At the time of the report, COVID-19 (She got Covid in January) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   On 17Nov2022, Patient received Pfizer bivalent booster (Lot No. GH6738; Expiry date: 17Nov2023) (Dosage: 30mcg in 0.3mL right arm by injection) for just thought a good idea and trying to stay current on vaccinations and experienced tingling in neck and cheek. She was moving her face and was moving through her body and went to the Hospital.  No treatment medications were reported.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Interchange of vaccine products, Swelling face, Swelling of eyelid
Clinical narrative: He has an eyelid edema also referred as a swelling in the eyelid; Eyebrow edema, more pronounced on the same side as the vaccination injection (left hand side).; DOSE 1, DOSE 2, DOSE 3: BNT162B2; DOSE 4: Moderna vaccine; DOSE 5: BNT162B2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 51-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Nov2022 at 18:15 as dose 5 (booster), single (Lot number: GJ6665) at the age of 51 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Seminoma of testis", start date: 20Jun2012 (unspecified if ongoing); "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medication(s) included: BENADRYL; ADVIL 12 HORAS. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Lot Number: EN6206, Anatomical location: Right arm), administration date: 09Mar2021, when the patient was 49-year-old, for COVID-19 immunisation; BNT162b2 (DOSE 2, SINGLE; Lot Number: ER8733, Anatomical location: Left arm), administration date: 30Mar2021, when the patient was 49-year-old, for COVID-19 immunisation; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Lot Number: FF2593, Anatomical location: Left arm), administration date: 17Oct2021, when the patient was 50-year-old, for COVID-19 immunisation; coviD-19 vaccine moderna (DOSE 4 (BOOSTER), SINGLE; Lot Number: 048L21A, Anatomical location: Left arm), administration date: 31Mar2022, when the patient was 50-year-old, for COVID-19 immunisation. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 15Nov2022 at 18:15, outcome "unknown", described as "DOSE 1, DOSE 2, DOSE 3: BNT162B2; DOSE 4: Moderna vaccine; DOSE 5: BNT162B2"; SWELLING FACE (non-serious) with onset 15Nov2022 at 23:00, outcome "recovering", described as "Eyebrow edema, more pronounced on the same side as the vaccination injection (left hand side)."; SWELLING OF EYELID (non-serious), outcome "unknown", described as "He has an eyelid edema also referred as a swelling in the eyelid". Therapeutic measures were not taken as a result of swelling face.  Additional information: The patient had no known allergy. The patient did not receive any other vaccine within the four weeks of vaccination. The patient had eyebrow edema, has an eyelid edema also referred as a swelling in the eyelid more pronounced on the same side as the vaccination injection (left hand side). Since the vaccination, the patient had not been tested for COVID-19.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: I had covid at the end of Aug, it's been 90 days since I recovered and tested negative.; I had covid at the end of Aug, it's been 90 days since I recovered and tested negative.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team and product quality group. The reporter is the patient.  A 73-year-old male patient received BNT162b2 (BNT162B2), on 02Mar2021 as dose 1, single (Batch/Lot number: unknown), on 23Mar2021 as dose 2, single (Batch/Lot number: unknown), on 29Sep2021 as dose 3 (booster), single (Lot number: 301558A) and on 04May2022 as dose 4 (booster), single (Lot number: PP4554) at the age of 72 years for covid-19 immunisation. The patient's relevant medical history included: "had flu shot just the other day" (unspecified if ongoing), notes: Prior Vaccinations (within 4 wk):had flu shot.Not within 4 weeks of 4th dose Covid shot, 4May2022. Concomitant medication(s) included: SIMVASTATIN taken for blood cholesterol abnormal. The following information was reported: VACCINATION FAILURE (medically significant) with onset 23Aug2022, outcome "unknown", COVID-19 (medically significant) with onset 23Aug2022, outcome "recovered" and all described as "I had covid at the end of Aug, it's been 90 days since I recovered and tested negative.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (23Aug2022) Positive, notes: Looks like he contracted Covid  23Aug2022 and it was gone 31Aug2022; (31Aug2022) Negative, notes: Positive for Covid: Looks like he contracted Covid  23Aug2022 and it was gone 31Aug2022. Paxlovid was taken as therapeutic measures for covid-19.  Clinical information: Patient periodically took 10mg Simvastatin to help keep his cholesterol numbers low and remove any plaque. Thought he was supposed to take it every day but his numbers have been very low, the last year and a half kind of stopped taking it and has asked doctor if ok to take it periodically or if he is still supposed to take every day. He has not been taking it.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, FLUX
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: had five Pfizer COVID vaccinations most recent on Sept/tested positive for COVID; had five Pfizer COVID vaccinations most recent on Sept/tested positive for COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 59-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Sep2022 as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Nov2022, outcome "not recovered" and all described as "had five Pfizer COVID vaccinations most recent on Sept/tested positive for COVID". It was reported that patient has had 5 Pfizer vaccinations and the most recent was the Bivalent in Sep2022. He tested positive for COVID on an unspecified date in Nov2022. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Nov2022) Positive.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.